CBLL News & Events

Reports Q4 revenue $24.78M, consensus $23.95M. "2025 was a milestone year for Ceribell," said co-founder and CEO Jane Chao. "We accelerated adoption across new and existing accounts, broadened the age range of our seizure detection algorithm to include pediatric and neonatal populations, and achieved critical regulatory milestones, unlocking incremental market opportunities that we believe exceed $1.5 billion. As we enter the new year, we believe these accomplishments position us well to drive continued growth and advance our long-term vision of making EEG a new vital sign."

The company said, "Ceribell expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29% over the company's prior year revenue."

CeriBell announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its Large Vessel Occlusion stroke detection monitor for patients in the hospital setting. The Breakthrough Device Designation for LVO Stroke builds on recent FDA 510(k) clearances for its next-generation Clarity algorithm to detect electrographic seizures in neonates and its proprietary delirium screening and monitoring solution, the company said.